Asset Details
Do you wish to reserve the book?
Enhancing the potency of in vivo lentiviral vector mediated gene therapy to hepatocytes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Enhancing the potency of in vivo lentiviral vector mediated gene therapy to hepatocytes
Do you wish to request the book?
Enhancing the potency of in vivo lentiviral vector mediated gene therapy to hepatocytes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Enhancing the potency of in vivo lentiviral vector mediated gene therapy to hepatocytes
2025
Overview
In vivo gene therapy to the liver using lentiviral vectors (LV) may represent a one-and-done therapeutic approach for monogenic diseases. Increasing LV gene therapy potency is crucial for reducing the effective doses, thus alleviating dose-dependent toxicities and facilitating manufacturing. LV-mediated liver transduction may be enhanced by positively selecting LV-transduced hepatocytes after treatment (
a posteriori
) or by augmenting the initial fraction of LV-targeted hepatocytes (a priori). We show here that the
a posteriori
enhancement increased transgene output without expansion of hepatocytes bearing LV genomic integrations near cancer genes, in mouse models of hemophilia, an inherited coagulation disorder. Furthermore, we enhanced hepatocyte transduction a priori in mice by transiently inhibiting antiviral pathways and/or through a fasting regimen. The most promising transduction-enhancer combination synergized with phagocytosis-shielded LV, resulting in a remarkable 40-fold increase in transgene output. Overall, our work highlights the potential of minimally invasive, cost-effective treatments capable of improving the potency of in vivo LV gene therapy to hepatocytes, in order to expand its applicability and ease clinical translation.
Lentiviral vectors are promising gene delivery vehicles to target hepatocytes in vivo, but restriction factors limit their efficiency. Here, the authors counteract many of these restrictions, amplifying lentiviral gene transfer into hepatocytes, strengthening its translational potential.
